Effect of phosphate binder therapy on FGF-23 levels in dialysis patients

Introduction . Fibroblast growth factor type 23 (FGF-23) inhibits phosphate reabsorption and vitamin D hormone synthesis in the kidneys. There is a known relationship between FGF-23 levels serum phosphate, as well direct correlation hyperphosphatemia risk of cardiovascular events. Aim To evaluate associations bone mineral metabolism patients on renal replacement therapy (RRT) with hemo- peritoneal dialysis, receiving not binders. Materials methods The study included 65 patients, which 43 received maintenance hemodialysis tratment (HD), 22 – dialysis (PD). control group consisted 28 healthy volunteers. Results increase concentration blood HD correlated vintage treatment (rs = 0,765; p 0,04). positive was found concentrations inorganic phosphorus 0,54; 0,03). level positively PTH 0,5; 0,01). In sevelamer carbonate lower, than (12.4 ± 5.9, 7.3, respectively; 0.003), (110 27 ng/mL, 340 15, 0.01). Conclusions directly “dialysis vintage”. use binders, particular carbonate, affects expression patients.